An EMA committee has recommended approval of Alvotech’s AVT06, a biosimilar to Bayer’s blockbuster ophthalmology drug Eylea.

Findings that U.S. companies can sue foreign rivals despite limited business operations in the country could dissuade drug ...

Eylea is the top-selling drug in the category, with sales approaching $10 billion in 2022, although, it could see biosimilar competition within the next few years. Bayer and Regeneron have sought ...

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...